A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...
Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...
Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access ...
The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...
Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...
Number 5: The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, ...
Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis, paving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback